BTIG Downgrades Foghorn Therapeutics to Neutral

BTIG analyst Jeet Mukherjee has downgraded Foghorn Therapeutics (NASDAQ: FHTX) from a 'Buy' rating to 'Neutral'. This change reflects a shift in the analyst's outlook on the company's performance.